Harmony Biosciences Holdings, Inc. Revenue 2020–2025
Harmony Biosciences Holdings, Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Harmony Biosciences Holdings, Inc. revenue for the quarter ending March 31, 2026 was 215.4 M, a 16.59% increase year-over-year.
- Harmony Biosciences Holdings, Inc. revenue for the twelve months ending March 31, 2026 was 899.1 M.
- Harmony Biosciences Holdings, Inc. annual revenue for 2025 was 868.5 M, a 21.51% increase from 2024.
- Harmony Biosciences Holdings, Inc. annual revenue for 2024 was 714.7 M, a 22.80% increase from 2023.
- Harmony Biosciences Holdings, Inc. annual revenue for 2023 was 582.0 M, a 32.93% increase from 2022.
- Harmony Biosciences Holdings, Inc. annual revenue for 2022 was 437.9 M.
Harmony Biosciences Holdings, Inc. (HRMY) — Frequently Asked Questions
Harmony Biosciences Holdings, Inc. (HRMY) is a publicly traded US company. It has a market capitalization of $2.04B. In fiscal 2025 it reported revenue of $868M and net income of $159M. Explore HRMY's stock price, financial statements, earnings history, margins and key ratios below.
What is Harmony Biosciences Holdings, Inc.'s market cap?
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalization of $2.04B.
What is the HRMY stock price?
HRMY trades at $35.48 (+4.05% on the day).
How much revenue does Harmony Biosciences Holdings, Inc. make?
Harmony Biosciences Holdings, Inc. reported revenue of $868M in fiscal 2025.
Is HRMY profitable?
In fiscal 2025, Harmony Biosciences Holdings, Inc. reported net income of $159M.
What is HRMY's P/E ratio?
Based on diluted EPS, HRMY has a price-to-earnings (P/E) ratio of about 13.1.